Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative chemoradiation with cisplatin, interferon alfa-2b, and 5-fluorouracil versus 5-fluorouracil alone in resected pancreatic adenocarcinoma
ISRCTN62866759Phase 3Completed
- Sponsor
- Heidelberg University
- Start
- Aug 2004
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, cisplatin, interferon alfa-2b and folinic acid in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Heidelberg University. Primary endpoint: Overall survival at two years postoperatively. Started Aug 2004; status: completed.
02
Drugs
fluorouracilcisplatininterferon alfa-2bfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN62866759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62866759.